AMARIN CORP. PLC REG.SHS(SP.ADRS NEW)/1 LS-,50 (WK
https://thefly.com/...ues-to-be-one-of-best-in-biotech-says-Jefferies
Ja, die shorts haben uns nach der "grandiosen Fehlentscheidung" solange in den Händen bis wir das Urteil revidiert bekommen, leider..... Ich habe Hoffung, Unrechtsrichterin Du (Vietkong) hat wegen "obviousness" gegen Amarin entschieden, d.h. Patente sind ungültig weil man wußte das EPA Triclyzride und die damit verbundenen Krankheiten wie Herzinfarkt, Schlaganfall.... reduziert..... Hier die beste These,dass es nicht so ist, warum hat dann big pharma mit AZN, GSK und Konsorten neue Trials mit EPA und DHA aufgelegt, wenn es offensichtlich war das hochreines EPA hilft..... Denkfehler, Prozessfehler, scheiss egal, das ist eine korrupte oder verblödete Richterin: cont. JT: Will bring tremendous shareholder value. Will vigorously fight. With all due respect, current court decision doesn't take into the value of Vascepa and goes against the finding of the USPTO. If it were obvious GSK, AZN would have gone with pure epa and not mixed epa/dha
Amarin - The Science Of Lipid Therapy | wallstreet-online.de - Vollständige Diskussion unter:
https://www.wallstreet-online.de/diskussion/...herapy#neuster_beitrag
Read more at:
https://thefly.com/landingPageNews.php?id=3071738
Hikma is working closely with the U.S. Food and Drug Administration (FDA) to gain approval for its Abbreviated New Drug Application (ANDA) for its generic version of Vascepa®. The company is evaluating its options for launching the product following FDA approval, including an at-risk launch in the event the District Court’s decision is appealed."
https://www.hikma.com/newsroom/...ing-in-generic-vascepa-patent-suit/
Anm.: at risk launch....das kann für Hikam gewaltig nach hinten losgehen,SOLLTE der Appeal erfolgreich sein( Schadensersatzklagen u.a., von Amarin ).
Mal schauen, ob sie sich noch trauen, wenn sie ....und wir....Näheres zum Appeal erfahren.
Der Hikma-Kurs seit dem "Gerichtsurteil" (....hust ) : naja bis gar nicht nachhaltig :-)
https://www.onvista.de/aktien/...ARMACEUTICALS-PLC-Aktie-GB00B0LCW083
09:07 AMRN
Roth Capital analyst Yasmeen Rahimi hosted a call with leading patent lawyer Shashank Upadhye to dive into the nuances behind the recent District Court ruling in favor of generics, as well as strategy and prospects surrounding Amarin's intended appeal to the Federal Court. The analyst notes that Upadhye puts high Probability of Success on Amarin's appeal, with "a winning appeal argument" likely focusing on District Court's take on primary versus secondary considerations. Rahimi has a Buy rating and a $31 price target on the shares."
Read more at:
https://thefly.com/landingPageNews.php?id=3073495
Patent lawyer puts high PoS on Amarin appeal, says Roth Capital 09:07 AMRN Roth Capital analyst Yasmeen Rahimi hosted a call with leading patent lawyer Shashank Upadhye to dive into the nuances behind the recent District Court ruling in favor of generics, as well as strategy and prospects surrounding Amarin's intended appeal to the Federal Court. The analyst notes that Upadhye puts high Probability of Success on Amarin's appeal, with "a winning appeal argument" likely focusing on District Court's take on primary versus secondary considerations. Rahimi has a Buy rating and a $31 price target on the shares.
Read more at:
https://thefly.com/landingPageNews.php?id=3073495
Roth Capital Partners, LLC ist eine kleine private Investmentbank mit Hauptsitz in Newport Beach, Kalifornien. Es ist spezialisiert auf Dienstleistungen für börsennotierte Small-Cap-Unternehmen.
Vor knapp einem Jahr :
"ROTH Capital Partners Acts as Co-Manager for Amarin Corporation
in its $460 Million Follow-On
Transaction Information
Amarin Corporation plc has closed an underwritten public offering of 25,555,556 American Depositary Shares ("ADSs"), which includes 3,333,333 additional shares pursuant to the full exercise of the over-allotment option granted to the underwriters. The ADSs were sold at the public offering price of $18.00 per ADS, resulting in the gross proceeds for Amarin of approximately $460 million.
Amarin intends to use the proceeds to........."
https://www.roth.com/files/marketing/email_blasts/AMRN_Jul2019.htm
Anm.: Letztendlich dürfte Roth Cap. eher ein Insider sein, m.M.n.,
mit einem KZ, der ......ambitioniert ist & den best case beschreibt.
"prolific writer and frequent speaker, Shashank is the author of numerous articles and the leading treatise on navigating complex U.S. laws of FDA brand/generic ...
Amin Talati & Upadhye is a boutique IP and FDA firm. We specialize in IP (patent and trademark) work, predominantly in the medical device and pharmaceutical ...
Patent lawyer specializing in pharmaceuticals, medical devices and related FDA law.
Formerly, chief IP and regulatory affairs counsel for several global drug ..."
Generic Pharmaceutical Patent and FDA Law...
Moderation
Zeitpunkt: 20.04.20 13:45
Aktionen: Löschung des Beitrages, Nutzer-Sperre für 1 Tag
Kommentar: Diskriminierung
Zeitpunkt: 20.04.20 13:45
Aktionen: Löschung des Beitrages, Nutzer-Sperre für 1 Tag
Kommentar: Diskriminierung
Amarin - The Science Of Lipid Therapy | wallstreet-online.de - Vollständige Diskussion unter:
https://www.wallstreet-online.de/diskussion/...herapy#neuster_beitrag
Procedural error: it looks like that Judge Du committed at least two errors
- Applied USPTO approach, determined prima facie obviousness and see secondary considerations (SCs) after that
- Weighted SCs against each others (plus gave a “negative” to some non-existing SCs)
Could it be enough?
The factual error – looks like it is important … the Apo-B / Kurabayashi (Kura):
- In case of Claim 8 of 677 patent: if Kura does not TSM and is not “obvious to try” the prima facie obviousness of the claim is weaker
- In case of ALL claims: the “unexpected benefit” exists … more doubt about obviousness
So, procedural error could be enough for reversal but with factual error the chance is definitely higher.
AMRN APPEAL :-)
21. April 2020 BENACHRICHTIGUNG ÜBER DOCKETING Federal Circuit Docket No.: 2020-1723 'S CLERK 202275 OFFICE 8000 Federal Circuit
Short Title: Amarin Pharma, Inc. gegen Hikma Pharmaceuticals USA
Datum der Notifizierung: 21. April 2020
Ursprüngliches Gericht: Bezirksgericht der Vereinigten Staaten für den Bezirk Nevada
Ursprüngliche Fallnummer: 2:16-cv-02525-MMD-NJK
Berufungskläger: Amarin Pharma, Inc., Amarin Pharmaceuticals Ireland Limited
Es wurde eine Berufungsschrift eingereicht, der die oben genannte Fallnummer des Federal Circuit zugewiesen wurde. Die offizielle Bildunterschrift des Gerichts ist als Anlage zu dieser Mitteilung beigefügt. Sofern in den Regeln des Gerichts nicht anders angegeben, müssen die zugewiesene Aktenzeichennummer und die offizielle Bildunterschrift oder der Kurztitel auf allen bei diesem Gericht eingereichten Dokumenten angegeben werden. Es liegt in der Verantwortung aller Parteien, die Regeln auf kritische Fälligkeitsdaten zu überprüfen. Der zugewiesene stellvertretende Gerichtsschreiber ist unten aufgeführt, und alle Fragen zum Fall sind an das Case Management Team unter (202) 275-8055 zu richten. Die folgenden Dokumente sind innerhalb von 14 Tagen nach dieser Mitteilung fällig: - Eintrag der Erscheinung. (Fed. Cir. R. 47.3.) - Bescheinigung über das Interesse. (Fed. Cir. R. 47.4.) - Erklärung über das Interesse. Hinweis: Das Docketing Statement ist innerhalb von 30 Tagen fällig, wenn die Vereinigten Staaten oder ihr Amt oder ihre Behörde eine Partei in der Berufung ist. ....Jeder Anwalt, der eine Partei vertritt, muss Mitglied der Anwaltskammer des Gerichts sein und für die elektronische Anmeldung des Gerichts registriert sein."
Jetzt kommt es darauf an, WELCHE litigation Firma als Rechtsbeistand ausgesucht wird....
Ich bin seeehr zufrieden mit Perkins Coie LLP, die ich, neben Susman,
auuuuuch im Washington Mutual Fall "kennengelernt" habe.
Und diese Kanzlei hat u.a. die Direktoren der Wamu erfolgreich verteidigt.
Für unseren Fall -hier zum Appeal- habe ich ein paar Highlights
der Referenzen hervorgehoben :
"Ranked #3 among "The Firms That Landed The Most Patent Suits Last Year" by Lex Machina, 2017
Named the most-hired firm by America’s largest companies for IP litigation by Corporate Counsel, 2017
Named to the “Appellate Hot List” by The National Law Journal, 2019
Named a "Top Patent Appellate Firm" by Law360, 2017
Named "Appellate Group of the Year" by Law360, 2017"
https://www.perkinscoie.com/en/about-us/firm/...verview/overview.html
Das alleine KANN schon mal Grund sein für ein vorzeitiges Settlement.
Oder AMRN pokert auf Appealerfolg.
Oder merged mit einem big player aus EUR.
"Unsere" wahrscheinlichen Gegner, meiner Meinung nach:
https://de.wikipedia.org/wiki/Kirkland_%26_Ellis
Ich bin seit über 10 Jahren in Amarin investiert und habe alle Höhen und Tiefen mitgemacht, kenne Vascepa und die einzigartigen Erfolge von allen trials beser als jeder andere hier und bin seit EUR 1,80 pro Aktie dabei, Du Schlaumeier!
Du hast keine Ahnung von der Materie, also unterlasse Deine mehr als lächerlichen Kommentare!
Was hier abgeht ist die Zerstörung geistigen Eigentums (kann bei RV10 gar nicht passieren) von Amarin, die 900 Millionen investiert haben um zu Game-Changing Ergebnissen zu kommen, Richterin Du hat offensichtlich falsch und korruptiv gehandelt, das muss rückgängig gemacht werden!
Schaun wir mal, wer Ahnung hat. PP oder Ihub.
Übrigens sitzen die Investierten hier in einem Boot, wollen hoffentlich dasselbe und sollten in
diesen Zeiten ERST RECHT friedlich und sachlich bleiben, meine Meinung.
In einem anderem board wurden sehr mysteriöse "Zufälle" in der Lebensvita von Du
aufgedeckt, die mich noch einmal mehr stutzig gemacht haben, ich hier aber nicht weiter
kommentieren möchte.
Ich bin zwar nicht direkt angesprochen worden, aber ich möchte sagen, daß ich nichts mehr hasse,
als gerichtliche Ungerechtigkeit, Korruptheit ....und die US laws.
Bin seit 2008 an der Börse tätig, in 2012 in einer Arivagruppe gegen JPM FDIC Hedgies kämpfend
( und immer noch wartend )
......ist Amarin ein deja-vu für mich.
Bei dem ich hoffe, daß Amarin und die Patienten/Konsumenten..... UND die Aktionäre.....
einen guten Ausgang erfahren werden.
Bleibt friedlich und stay safe.
factual and procedur erros gemacht hat.....
Yes we hope....
Traurig, dass es soweit kommen musste, aber wo es um viel Geld geht, ist immer Korruption..... dabei
"It's confirmed the new lead counsel will be Fish & Richardson, on Forbes list of america's top law firms...."
Search on PACER April 21, 2020
"Entry of appearance for Jonathan E. Singer as principal counsel for Appellants Amarin Pharma, Inc."
WENN dem wirklich so ist :
Mr. Singer is annually named one of the nation’s finest life sciences trial attorneys and is an expert in proceedings under the Hatch-Waxman Act. His clients consistently praise his innovative and ground-breaking work and over the past two decades, he has successfully handled dozens of cases covering all aspects of the life sciences. In addition to his courtroom work, Mr. Singer regularly teaches life sciences trial and patent practice courses in the U.S. and Europe.
"Forbes list america's top corporate law firms"
"Last month, Fish was named one of three elite "IP Litigation Powerhouses" in the prestigious BTI Litigation Outlook 2020 survey. Fish was the only firm to appear on the list in two consecutive years. Fish was also named one of 10 "Awesome Opponents" in BTI's list of the "Most Feared Law Firms in Litigation." The BTI survey is based solely on in-depth telephone interviews with leading litigation decision-makers at large organizations with $1 billion or more in revenue."
Perkins Coie ist damit für mich noch nicht gegessen und eigentlich mein Favorit.
Oder WAREN diese bisher tätig für Amarin ? Weiß jemand von den Mitlesenden hier mehr ?
Ich halte die Wahl der Rechtvertretung für enorm, enorm wichtig...
Amarin and Atara Biotherapeutics could both be diamonds in the rough.
George Budwell
George Budwell
(TMFGBudwell)
Apr 27, 2020 at 7:56AM
Author Bio
Stocks priced below $10 a share can be a mixed bag. Low share prices are often indicative of companies with poor fundamentals, a weak near-term outlook, and a large number of outstanding shares. These types of equities, in turn, tend to be exceptionally risky and highly volatile from a price standpoint. But there are a few significant upsides to buying stocks in the $5 to $10 range.
Low-priced equities, on occasion, can deliver substantial returns on capital within an exceedingly short period. What's more, it's far easier to build a position in round lots of 100 shares at a time. By doing so, investors can reduce their risk profile and generate immediate cash from the position by selling call options. While selling calls can cap the maximum return from a low-priced equity, this strategy also ensures that you won't walk away empty-handed in a worst-case scenario.
A man wearing sunglasses while throwing money into the air.
Image source: Getty Images.
Which companies with share prices under $10 should investors be paying attention to right now? Two of the best low-priced equities at the moment are Amarin (NASDAQ:AMRN) and Atara Biotherapeutics. (NASDAQ:ATRA). These two biotech stocks have been heating up over the course of April and both are seemingly undervalued relative to their long-term outlook. Here's a snapshot of the pros and cons of each company.
Amarin: A bet on a full-blown comeback
Amarin is a single-product, commercial-stage biopharma. The company's value proposition thus begins and ends with its prescription omega-3 treatment Vascepa. Last year, the drug gained a major label expansion as a treatment for patients taking statins but who are still at risk of cardiovascular disease. This new indication was thought to be worth at least $2 billion in annual sales, and possibly quite a bit more. Unfortunately, a U.S. District Court stripped Vascepa of its patent protection in March, causing Amarin's shares to collapse.
Thanks to the growing optimism that this decision will be overturned upon appeal, Amarin's shares have gained 88% in the nearly four weeks since this adverse ruling. This rapid recovery has also been fueled by the fact that Vascepa could still achieve blockbuster status, regardless of this patent ruling, due to its healthy commercial opportunity in former U.S. territories.
What are the risks and rewards? With a successful appeal in hand, Amarin's shares should rise by at least another 70% from current levels in light of where this stock was trading prior to this black swan event. If this appeal fails, however, Amarin should ultimately settle at around $8 a share -- based on Vascepa's commercial opportunity in the former territories and the average pre-pandemic premium for a commercial-stage biopharma stock. So, even in a worst-case scenario, Amarin's shares are arguably still undervalued right now.
Atara: A make-or-break moment is on the way
Atara is a cell-based immunotherapy company. The company's main selling point to investors is its leadership position in the field of off-the-shelf T-cell therapies for cancer, autoimmune disorders, and viral infections. Atara's strategy centers around launching the first off-the-shelf T-cell therapy, dubbed tab-cel, for patients with Epstein-Barr virus associated post-transplant lymphoproliferative disease as soon as next year. A regulatory filing for this first-of-its-kind therapy is slated for the second half of 2020.
Although tab-cel's peak sales are expected to be rather modest at around $140 million a year, the company's second product candidate, ATA188, could be a megablockbuster as a novel treatment for patients with progressive multiple sclerosis. What's more, Atara's buyout value should skyrocket if its cell-based platform is validated with a successful regulatory filing for tab-cel. There are several big pharmas and blue-chip biotech companies racing to develop similar technologies after all.
What's the risk? While Atara does have the inside track for becoming the first company to bring an off-the-shelf T-cell therapy to market, there's also no guarantee that this novel therapy will get a green light from regulators. That's a significant risk factor to be sure. Atara's shares, in short, will surely take a huge step backward if tab-cel stumbles in the clinic or fails to win over regulators. On the flip side, this small-cap biotech stock does have the potential to double (or possibly triple) in value in the event that tab-cel does live up to expectations.
Bottom line: Atara is the epitome of a high-risk, high-reward clinical-stage biotech stock. Invest accordingly.